Shanghai Henlius Biotech Gets Australian Approval for Phase 3 Trials for Postmenopausal Osteoporosis Injectable
Shanghai Henlius Biotech Gets Australian Approval for Phase 3 Trials for Postmenopausal Osteoporosis Injectable
上海亨利乌斯生物科技公司获得澳大利亚批准进行绝经后骨质疏松症注射剂3期试验
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册